An innovative bio-based platform for the cost-competitive production of L-Fucose, a building block for Human Milk Oligosaccharides (HMOs)

Projektinformationen

FucoPol

ID Finanzhilfevereinbarung: 736566

DOI

10.3030/736566

Projekt abgeschlossen

EK-Unterschriftsdatum 29 Juli 2016

Startdatum 1 August 2016

Enddatum 30 November 2016

Finanziert unter

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

SETENTA E TRES MIL E CEM LDA
Portugal

Periodic Reporting for period 1 - FucoPol (An innovative bio-based platform for the cost-competitive production of L-Fucose, a building block for Human Milk Oligosaccharides (HMOs))

Berichtszeitraum: 2016-08-01 bis 2016-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Currently a large scale production of HMOs is not feasible due to the complexity and costs related to increasing availability of L-fucose. 73100 has developed and patented a novel bacterial biopolymer - FucoPol - as a natural source for the efficient and cost-competitive production of pure L-fucose. The main objective of the project is to demonstrate and validate the scalability of the platform, proving its usefulness for industrial-scale production.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the project, 73100 accomplished a full analysis of the technical and business potential of FucoPol – the innovative bio-based platform for the production of L-fucose. In Phase 1, 73100 determined exactly what capabilities would be required from third parties both for the project duration and full commercial rollout. Through an extensive search of potential partners to support the scale-up activities the company were able to confirm the availability of Biotrend and Cipan for the project. Both companies have strong industrial biotechnology expertise, state-of-the-art facilities and both are also located in Portugal.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

73100 is set to become the world’s first large scale L-fucose producer. Current technologies are hindered by the complexity and costs related to the attempt to increase the availability of the core component, L-fucose. The innovative technology – on which the FucoPol production is based – entails its use as a natural platform to generate pure carbohydrates (fucose, galactose, glucose and glucuronic acid), either in mixtures with defined composition or as individual monosaccharides. Depending on the application of L-fucose, 73100 has the potential to sell to several different customer types. 73100 have identified the most desired applications for FucoPol derived products, mainly L-fucose, and have identified companies engaged in chemical synthesis for HMO’s, manufacturing of prebiotic food/beverages, pharmaceuticals, and cosmetics. 73100 has the potential to first sell to chemical reagent distributors in Europe and North America. 73100 expects rapid growth once commercialized and increased profitability as their product is sold for new HMO applications (e.g. as a novel food ingredient). 73100 also has the potential to address relevant challenges faced by many European societies – mainly related to providing an adequate supply for high-quality food while enhancing innovation and sustainability in the production processes. In fact, glycoscience in Europe is fast becoming an essential part of modern innovative biotechnology and having access to state-of-the-art knowledge and technologies in this sector will provide the European bio-based industries with a strong competitive advantage on a worldwide stage.

73100.jpg